Van K. Morris, MD, discusses the findings of the KEYNOTE-158 trial, which evaluated pembrolizumab in advanced solid tumors in relation to patients with advanced unresectable anal cancer.
Van K. Morris
Advertisement
Articles by Van K. Morris
Van K. Morris, MD, describes the novel treatments he is excited about in the treatment landscapes for colorectal and anal cancers right now.
Advertisement
Latest Updated Articles
Pembrolizumab Shows Durable Response in Advanced Unresectable Anal CancerPublished: May 19th 2020 | Updated:
Discussing the Novel Treatments in Colorectal and Anal CancerPublished: March 4th 2020 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
